Summary
The pharmacokinetics of bupropion and 3 of its basic metabolites were determined in 8 young, healthy, male volunteers after single and multiple oral doses of bupropion. Plasma profiles were obtained: 1) after a single 100 mg oral dose of bupropion hydrochloride, 2) following administration of 100 mg 8-hourly for 14 days and 3) again after a single 100 mg dose 14 days later. Plasma concentrations of the parent drug and metabolites were determined by high-performance liquid chromatography. Saliva secretion and pupil diameters were measured, subjective assessments of sleep made using visual analogue scales and side effects, blood counts and biochemistry were monitored. After the first dose mean elimination half lives (t1/2) of bupropion, and metabolites I and II were 8, 19 and 19 h respectively. On repeated administration there was little accumulation of the parent drug and no evidence for induction of its own metabolism. Accumulation of I was consistent with its rate of elimination after single doses while that of II was greater than predicted with prolongation of t1/2 to 35 h. Metabolite III was barely detectable after single doses but its accumulation on multiple dosing was consistent with its long half life (35 h) determined on occasion 2. Saliva secretion was significantly reduced during the multiple dosing period but there were no complaints of dry mouth. Subjective assessments of sleep were not significantly altered though one subject reported vivid dreams. There were no other adverse reactions.
Similar content being viewed by others
Abbreviations
- ka :
-
first order rate constant for absorption or appearance
- kel :
-
first order rate constant for elimination
- F:
-
extent of bioavailability
- D:
-
administered dose (as free base)
- k12 :
-
first order distribution rate constant into peripheral compartment
- k21 :
-
first order distribution rate constant from peripheral compartment
- k10 :
-
first order elimination rate constant from central compartment
- α:
-
first order elimination rate constant of rapid disposition phase
- β:
-
first order elimination rate constant of slow disposition phase
- Vz :
-
apparent volume of distribution
- Vc :
-
apparent volume of distribution of central compartment
- t:
-
time after drug administration
- to :
-
lag time for absorption
- Cp(t) :
-
concentration in plasma at time t
- n:
-
number of doses
- Cp(tn) :
-
concentration in plasma at time t after nth dose
- τ:
-
dose interval
- CL:
-
clearance uncorrected for bioavailability F
References
Schroeder DH, Hinton ML, Smith PG, Nichol CA, Welch RM (1978) A method of analysis for bupropion and its disposition in animals and man. Fed Proc 37: 691
Conney AH (1967) Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 19: 317–366
Park BK, Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1–24
Gelehrter TD (1976) Enzyme induction. N Engl J Med 294: 589–595
Vessell ES (1980) The value of antipyrine and aminopyrine as model substrates in assessing drug-metabolising capacity in man. TIPS 1 [16]: IV-V
Park BK (1981) Assessment of urinary 6-β-hydroxycortisol as an in vivo index of mixed-function oxygenase activity. Br J Clin Pharmacol 12: 97–102
Hunter J, Maxwell JD, Carrella M, Steward DA, Williams R (1971) Urinary D-glucaric acid excretion as a test for hepatic enzyme induction in man. Lancet 1: 572–584
Whitfield JB, Moss DW, Neale G, Orme M, Breckenridge A (1973) Changes in plasma gamma glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br Med J 1: 316–318
Rapeport WG, McInnes GT, Thompson GG, Forrest G, Park BK, Brodie BJ (1983) Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: Studies with carbamazepine. Br J Clin Pharmacol 16: 133–137
Gerardin AP, Abadhe FV, Campestrini JA, Theobald W (1976) Pharmacokinetics of carbamazepine in normal humans after single and repeated oral doses. J Pharmacokinet Biopharm 4: 521–535
Nitti V, Delli V, Ninni A, Meola G (1972) Rifampicin blood serum levels and half life during prolonged administration in tuberculosis patients. Chemotherapy 17: 121–129
Nitti V, Ninni A, Meola G, Iuliano A, Curci G (1973) Comparative investigations of the enzyme-inducing activity of rifampicin and barbiturates in man. Chemotherapy 19: 206–210
Zung WWK (1983) Review of placebo controlled trials with bupropion. J Clin Psychiatry 44 (5) [Sec 2]: 104–114
Lader M (1975) The psychophysiology of mental illness. Routledge and Kegan Paul, London, p 29
Cooper TB, Suckow RF, Glassman A (1984) Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual wave length UV detection. J Pharm Sci 73: 1104–1107
Sedman AJ, Wagner JG (1974) CSTRIP a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65: 1006
Metzler CM, Elfring GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modelling. Biometrics 30: 362
Findlay JWA, Fleet JVW, Smith PG, Butz RF, Hinton ML, Blum MR, Schroeder DH (1981) Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Europ J Clin Pharmacol 21: 127–135
Becker RE, Dufresne RL (1982) Perceptual changes with bupropion, a novel antidepressant. Am J Psychiatry 139: 1200–1201
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Posner, J., Bye, A., Dean, K. et al. The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur J Clin Pharmacol 29, 97–103 (1985). https://doi.org/10.1007/BF00547376
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00547376